| (USD) | Dec 2022 | Q/Q |
|---|---|---|
| Revenue | 0 | - |
| Operating Income | - | - |
| Operating Expenses | - | - |
| Net Income | - | - |
| R&D | - | - |
| G&A | - | - |
| Interest Expense | 312K | +19% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Post-merger, the combined company is expected to operate under the name Korro Bio, Inc.
LEXINGTON, Mass., August 10, 2023--Frequency Therapeutics, Inc. (Nasdaq: FREQ) today announced business updates and financial results for the second quarter ended June 30, 2023.
Post-merger, Frequency (FREQ) focuses on advancing RNA editing programs. This combined entity is set to operate under the name Korro Bio, which will apply to trade on the NASDAQ under the ticker symbol KRRO.
Korro Bio Inc and Frequency Therapeutics Inc (NASDAQ: FREQ) announced an all-stock merger transaction. Under the merger agreement's terms, stockholders of Korro Bio will receive newly issued shares of Frequency Therapeutics. Frequency Therapeutics has discontinued developing its remyelination program for Multiple Sclerosis as it explores strategic alternatives for the program. Suppose Frequency Therapeutics has not otherwise monetized its remyelination program before the closing of the proposed
CAMBRIDGE & LEXINGTON, Mass., July 14, 2023--Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc. (Nasdaq: FREQ) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs, is expected to operate under Korro Bio, Inc. and will apply to
LEXINGTON, Mass., May 12, 2023--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the first quarter ended March 31, 2023.
LEXINGTON, Mass., March 10, 2023--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2022.
LEXINGTON, Mass., February 27, 2023--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that interim Chief Executive Officer and Chief Scientific Officer Christopher Loose, Ph.D., will present at the following March healthcare investor conferences:
The layoffs announced Monday are tied to bad news from a mid-stage clinical trial of Frequency Therapeutics' lead drug, FX-322.
Frequency Therapeutics Inc (NASDAQ: FREQ) announced clinical results from the Phase 2b study of FX-322 in individuals with acquired Sensorineural Hearing Loss (SNHL). The study, which enrolled 142 people with either sudden or noise-induced sensorineural hearing loss, failed to achieve its primary efficacy endpoint of improving speech perception. Data showed no statistically meaningful difference at day 90 between those administered FX-322 versus those receiving a placebo in the proportion of ind